Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer.

ABSTRACT: Local cryoablation can engender systemic immune activation/anticancer responses in tumors otherwise resistant to immune checkpoint blockade (ICB). We evaluated the safety/tolerability of preoperative cryoablation plus ipilimumab and nivolumab in 5 early-stage/resectable breast cancers. The primary endpoint was met when all 5 patients underwent standard-of-care primary breast surgery undelayedly. Three patients developed transient hyperthyroidism; one developed grade 4 liver toxicity (resolved with supportive management). We compared this strategy with cryoablation and/or ipilimumab. Dual ICB plus cryoablation induced higher expression of T cell activation markers and serum Th1 cytokines and reduced immunosuppressive serum CD4⁺PD-1^hi T cells, improving effector-to-supp

SUBMITTER: Comen E 

PROVIDER: S-EPMC10850740 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature